Therefore, BCAA supplementation (≈12.5 g/day) can hold promise in inhibiting the development of atherogenesis, particularly in patients with a high cardiovascular risk such as those with familial hypercholesterolemia, which is mirrored by the knockout of the Apoe gene and a rise in both total and low-density lipoprotein cholesterol in the respective mouse models. This evidence concerns the gene APOE and familial hypercholesterolemia.